Eisai, Inc. voluntarily withdrew the weight loss medication Belviq and Belviq XR (lorcaserin) from the U.S. market following a U.S. Food and Drug Administration request. Data showed that patients who had taken the drug as part of a large clinical safety trial showed an increased occurrence of cancer five years later. 7.7% of the lorcaserin subjects developed cancer, compared to the placebo group. Cancers observed included pancreatic, colorectal, and lung.